Promoter methylation of the repair gene O6-methylguanine-DNA methyltransferase (MGMT) is a predictive factor for benefit from alkylating agent therapy in glioblastoma patients [3, 16, 33]. The gene discussed is MGMT; the disease is glioblastoma.